Skip to main content

Market Overview

The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight

The Week Ahead In Biotech April 26-May 2: Cancer Conference, Earnings News Flow In The Spotlight

The week ended April 24 turned out to be an up-and-down one for biotech stocks, as the sector swayed along with the broader market. Two FDA approvals came through this week, with Immunomedics, Inc.'s (NASDAQ: IMMU) breast cancer drug snagging an FDA nod and Sanofi SA's (NASDAQ: SNY) meningococcal vaccine greenlighted by the regulatory agency.

First-quarter earnings were healthy, although the same cannot be said of the forward outlook given the uncertainty associated with the COVID-19 pandemic. Biogen Inc (NASDAQ: BIIB) came under pressure on a delay in the regulatory filing for its Alzheimer's drug.

The following are key catalysts that could sway biotech stocks in the unfolding week:


  • American Association for Cancer Research, or AACR, 2020 Virtual Annual Meeting: April 27-28


  • The FDA is set to rule on Neurocrine Biosciences, Inc.'s (NASDAQ: NBIX) NDA for Opicapone, a once-daily, oral, selective catechol-O-methyltransferase inhibitor that is being evaluated as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes. (Sunday)
  • The FDA will also decide on United Therapeutics Corporation's (NASDAQ: UTHR) NDA for Trevyent. Trevyent is a drug-device combination product that combines two-day, single use, disposable PatchPump technology with treprostinil, for the subcutaneous treatment of pulmonary arterial hypertension. (Monday)
  • Pfizer Inc. (NYSE: PFE) awaits the FDA decision on its sNDA for Braftovi in combination with Bristol-Myers Squibb Co's (NYSE: BMY) Erbitux. The Braftovi-Erbitux combo is being evaluated as a treatment option for patients with advanced BRAFV600E-mutant metastatic colorectal cancer, following one or two lines of therapy. (April schedule)
  • Amgen, Inc.'s (NASDAQ: AMGN) sNDA for Otezla to expand the prescribing information to include data from the Phase 3 scalp psoriasis study is under review by the FDA. The PDUFA action date is in April.

See also: Some Biogen Analysts Unimpressed By Explanation For Aducanumab Filing Delay

Clinical Readouts

AACR Virtual Conference Presentations


  • Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI): Data from Cohort 1 of a Phase 2 study that evaluated poziotinib in non-small cell lung cancer with exon 20 insertion mutation in EGFR or HER2
  • Syndax Pharmaceuticals Inc (NASDAQ: SNDX): updated Phase 1 data for SNDX-5613 in relapsed/refractory acute leukemia.
  • Verastem Inc (NASDAQ: VSTM): Phase 1 data for VS-6766, its RAF/MEK inhibitor, in combination with defactinib, its FAK inhibitor, in patients with KRAS mutant advanced solid tumors.
  • Compugen Ltd. (NASDAQ: CGEN): Phase 1 data for COM701 and Bristol-Myers Squibb's Opdivo in solid tumors.
  • IMMUTEP LTD/S ADR (NASDAQ: IMMP): Initial Phase 1 results for eftilagimod alpha and Merck & Co., Inc.'s (NYSE: MRK) Keytruda in non-small cell lung cancer and head and neck cancer.
  • Idera Pharmaceuticals Inc (NASDAQ: IDRA): updated Phase 2 data for tilsotolimod along with Opdivo and Yervoy in squamous cell carcinoma of the head and neck.
  • Moderna Inc (NASDAQ: MRNA): Phase 1/2 data for mRNA-2416 and durvalumab in advanced malignancies.
  • GlaxoSmithKline plc (NYSE: GSK): Phase 1 data for GSK3174998 in solid tumors.
  • Sutro Biopharma Inc (NASDAQ: STRO): updated Phase 1 data for STRO-002 in ovarian and endometrial cancer.


  • Iovance Biotherapeutics Inc (NASDAQ: IOVA): Phase 1 data for tumor-infiltrating lymphocytes in non-small cell lung cancer.

The Other Readouts

  • Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi: initial Phase 2/3 Kevzara data (April).
  • Gilead Sciences, Inc. (NASDAQ: GILD): Phase 3 data for remdesivir in COVID-19 severe patients (late-April).
  • Ovid Therapeutics Inc (NASDAQ: OVID): Phase 2 top-line data for OV101 in Fragile X syndrome (Early Q2).
  • Iterum Therapeutics PLC (NASDAQ: ITRM): Phase 3 data for Sulopenem in uncomplicated and complicated urinary tract infections (Early Q2).
  • Atossa Therapeutics Inc (NASDAQ: ATOS) will meet with the FDA Thursday to discuss the clinical development of oral Endoxifen to reduce mammographic breast density.



  • Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) (before the market open)


  • Merck & Co., Inc. (NYSE: MRK) (before the market open)
  • Pfizer Inc. (NYSE: PFE) (before the market open)
  • NeoGenomics, Inc. (NASDAQ: NEO) (before the market open)
  • Masimo Corporation (NASDAQ: MASI) (after the close)
  • Medpace Holdings Inc (NASDAQ: MEDP) (after the close)
  • DexCom, Inc. (NASDAQ: DXCM) (after the close)


  • Alkermes Plc (NASDAQ: ALKS) (before the market open)
  • Boston Scientific Corporation (NYSE: BSX) (before the market open)
  • United Therapeutics Corporation (NASDAQ: UTHR) (before the market open)
  • Alimera Sciences Inc (NASDAQ: ALIM) (after the close)
  • AtriCure Inc. (NASDAQ: ATRC) (after the close)
  • BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) (after the close)
  • Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) (after the close)
  • SurModics, Inc. (NASDAQ: SRDX) (after the close)
  • Hologic, Inc. (NASDAQ: HOLX) (after the close)


  • Agios Pharmaceuticals Inc (NASDAQ: AGIO) (before the market open)
  • ABIOMED, Inc. (NASDAQ: ABMD) (before the market open)
  • BIO-TECHNE Corp (NASDAQ: TECH) (before the market open)
  • Syneos Health Inc (NASDAQ: SYNH) (before the market open)
  • PRA Health Sciences Inc (NASDAQ: PRAH) (before the market open)
  • Lantheus Holdings Inc (NASDAQ: LNTH) (before the market open)
  • Iradimed Corp (NASDAQ: IRMD) (before the market open)
  • Concert Pharmaceuticals Inc (NASDAQ: CNCE) (before the market open)
  • Amgen, Inc. (NASDAQ: AMGN) (after the close)
  • Emergent Biosolutions Inc (NYSE: EBS) (after the close)
  • Insmed Incorporated (NASDAQ: INSM) (after the close)
  • Gilead Sciences, Inc. (NASDAQ: GILD) (after the close)
  • Seattle Genetics, Inc. (NASDAQ: SGEN) (after the close)
  • Natus Medical Inc (NASDAQ: NTUS) (after the close)
  • Illumina, Inc. (NASDAQ: ILMN) (after the close)
  • PTC Therapeutics, Inc. (NASDAQ: PTCT) (after the close)
  • LeMaitre Vascular Inc (NASDAQ: LMAT) (after the close)
  • ResMed Inc. (NYSE: RMD) (after the close)
  • Viking Therapeutics Inc (NASDAQ: VKTX) (after the close)
  • Silk Road Medical Inc (NASDAQ: SILK) (after the close)
  • Corvus Pharmaceuticals Inc (NASDAQ: CRVS) (after the close)
  • CareDx Inc (NASDAQ: CDNA) (after the close)
  • Tandem Diabetes Care Inc (NASDAQ: TNDM) (after the close)


  • AbbVie Inc (NYSE: ABBV) (before the market open)
  • GlycoMimetics Inc (NASDAQ: GLYC) (before the market open)
  • ImmunoGen, Inc. (NASDAQ: IMGN) (before the market open)

IPO Quiet Period Expiry

  • Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL)

Related Link: BioNTech, Immunic Soar On COVID-19 Developmental Updates


Related Articles (XBI + IBB)

View Comments and Join the Discussion!

Posted-In: Biotech Earnings News Previews FDA IPOs Trading Ideas Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at